Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13043801 | 0.90 | CTSK (0.54) | ALDH1A1GAACTSKCTSLCTSB | |
| SCHEMBL14601914 | 0.90 | CTSK (0.54) | ALDH1A1GAACTSKCTSLCTSB | |
| SCHEMBL14337553 | 0.85 | CASP3 (0.53) | ALDH1A1GAACTSKCTSLCTSB | |
| SCHEMBL13043811 | 0.85 | CASP3 (0.53) | ALDH1A1GAACTSKCTSLCTSB | |
| SCHEMBL253913 | 0.84 | ALDH1A1 (0.53) | ALDH1A1GAACTSKCTSLCTSB | |
| SCHEMBL4679772 | 0.82 | TSHR (0.53) | ALDH1A1GAACTSKCTSLCTSB | |
| SCHEMBL4683464 | 0.82 | TSHR (0.53) | ALDH1A1GAACTSKCTSLCTSB | |
| SCHEMBL4679774 | 0.82 | TSHR (0.53) | ALDH1A1GAACTSKCTSLCTSB | |
| SCHEMBL13244921 | 0.81 | ALDH1A1 (0.51) | ALDH1A1GAACTSKCTSLCTSB | |
| SCHEMBL18712231 | 0.81 | ALDH1A1 (0.51) | ALDH1A1GAACTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | ALDH1A1 2624/4885GAA 4327/4885CTSK 2516/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 2395/4885GAA 3911/4885CTSK 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.